|
|
|
|
Traws Pharma inc (NASDAQ: TRAW) |
|
Price: $1.6700
$0.02 
1.212%
|
| Day's High:
| $1.7673
| Week Perf:
| -7.22 %
|
| Day's Low: |
$ 1.65 |
30 Day Perf: |
24.63 % |
| Volume (M): |
210 |
52 Wk High: |
$ 12.25 |
| Volume (M$): |
$ 351 |
52 Wk Avg: |
$5.58 |
| Open: |
$1.70 |
52 Wk Low: |
$0.97 |
|
|
| Market Capitalization (Millions $) |
3 |
| Shares
Outstanding (Millions) |
2 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
0 |
| Net Income (TTM) (Millions $) |
-55 |
| Cash Flow (TTM) (Millions $) |
-4 |
| Capital Exp. (TTM) (Millions $) |
4 |
Traws Pharma Inc
Company Address: 12 Penns Trail Newtown 18940 PA
Company Phone Number: 759-3680 Stock Exchange / Ticker: NASDAQ TRAW
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Management Changes
Published Fri, Mar 28 2025 8:30 PM UTC
Traws Pharma in Transition: Charting a Course through Financial Struggles and Promising InnovationsNEWTOWN, Pa.?In a surprising move, Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company at the forefront of developing therapies against respiratory viral diseases, announced the retirement of its Chief Executive Officer, Dr. Werner Cautreels, effect...
|
| Clinical Study
Published Mon, Mar 24 2025 11:48 AM UTC
: Traws Pharma, Inc. has unveiled significant progress in its antiviral bird flu program, announcing positive topline results from a pivotal study utilizing tivoxavir marboxil (TXM). This investigational oral small molecule, designed to inhibit CAP-dependent endonucleases, demonstrates potential as a single-dose treatment against H5N1 avian influenza in non-human primates. T...
|
| Clinical Study
Published Thu, Nov 14 2024 9:30 PM UTC
In a rapidly evolving biopharmaceutical sector, Traws Pharma, Inc. has emerged as a notable player, particularly within the sphere of oral therapeutics for respiratory viral diseases. The company, headquartered in Newtown, Pennsylvania, recently provided a comprehensive business update and unveiled its financial results for the third quarter of 2024. As Traws Pharma continue...
|
| Clinical Study
Published Tue, Oct 8 2024 11:30 AM UTC
Traws Pharma, a rising biopharmaceutical company, has recently released encouraging Phase 1 data for its investigational antiviral drug, Tivoxavir Marboxil. The novel agent, designed for single-dose treatment or prevention of both seasonal and pandemic influenza, demonstrated efficacy and safety in early clinical trials. However, despite these promising scientific developmen...
|
| Clinical Study
Published Mon, Sep 30 2024 11:30 AM UTC
: The pharmaceutical landscape has been profoundly impacted by the emergence of COVID-19, necessitating rapid innovation in antiviral therapies. Traws Pharma?s recent announcement regarding the topline results from a Phase 1 clinical trial offers significant insights into the therapeutic potential of Ratutrelvir, an oral Mpro inhibitor aimed at combating COVID-19. This art...
|
| Per Share |
Current |
| Earnings (TTM) |
-30.45 $ |
| Revenues (TTM) |
0.15 $
|
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-30.45 $
|
| Revenues (TTM) |
0.15 $ |
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
